The importance of B cells in multiple sclerosis (MS) has been demonstrated through the
advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human …

Background: Distinctive differences in multiple sclerosis (MS) have been observed by race
and ethnicity. We aim to (1) assess how often race and ethnicity were reported in clinical …

Background In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are
used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered) …

Background: Evidence from network meta-analyses (NMAs) and real-world propensity score
(PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over …

Background Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, has shown
promising efficacy in limited cases of neuromyelitis optica spectrum disorder, but there is a …

Background The management of Multiple Sclerosis (MS) has undergone transformative
evolution with the introduction of high-efficacy disease-modifying therapies (DMTs) …

Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the
progression of relapsing multiple sclerosis. Originally approved by the Food and Drug …

I trattamenti di fondo della sclerosi multipla che beneficiano di autorizzazione al rimborso da
parte delle autorità sanitarie si sono moltiplicati negli ultimi 15 anni, con, attualmente, una …

2 subjects were divided into four groups or quartiles representing four dosing levels based
on measuring peripheral blood drug concentrations (Hauser et al. 2023). Although there …

The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-
remitting multiple sclerosis: A network meta-analysis. The progress in understanding the …